Recently, the first patient was enrolled and dosed in a Phase III registrational clinical trial at the General Hospital of Pingmei Shenma Medical Group. The trial is for Cafelkibart (LM-108, a CCR8 monoclonal antibody), a Class 1 innovative drug independently developed by LaNova Medicines, a wholly-owned subsidiary of Sino Biopharmaceutical Limited (SBP Group, 1177.HK).

When a malignant tumor invades the serous layer of the thoracic or abdominal cavity, it can lead to abnormal fluid accumulation, causing dyspnoea, abdominal distension, anorexia, etc., which severely affect the patient's quality of life.

Recently, Chia Tai Tianqing, the core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), received a formal notification from the European Medicines Agency (EMA) that the company has successfully passed the comprehensive review of EU GMP compliance inspection and has been awarded the EU GMP certificate for human medicinal products. Since first passing the EMA inspection in 2014, Chia Tai Tianqing has passed the EU GMP certification to a high standard five consecutive times, with multiple products entering the EU market to benefit patients worldwide.

On May 6, the website of the National Medical Products Administration (NMPA) showed that the second indication for Culmerciclib Capsules, independently developed by Chia Tai Tianqing, the core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), has been approved for marketing.

On April 29, Chia Tai Tianqing, the core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), once again joined hands with the Greater China Cancer Care Foundation (hereinafter referred to as "the Foundation") to officially include the world's first CDK2/4/6 inhibitor, Culmerciclib Capsules, into the Compassionate Corporate Partner NPP Cooperation Agreement, bringing a new treatment option to breast cancer patients in Hong Kong with urgent treatment needs. Dr. Cheng Kam-chung, Founder and Chairman of the Board of the Foundation, and Liu Liang, Assistant Vice President and General Manager of the Business Unit at Chia Tai Tianqing, attended the signing ceremony.

On the morning of April 25, a delegation led by Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League and Chairman of the All-China Youth Federation, visited CTTQ, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), for inspection and guidance.

Chemotherapy is one of the core methods of tumor treatment, but chemotherapy-induced neutropenia (CIN) is the most common hematological adverse event in clinical practice. The resulting febrile neutropenia (FN) can lead to chemotherapy dose reduction, delays, and even endanger patient safety. On April 23, the "Chinese Expert Consensus on the Diagnosis and Treatment of Chemotherapy-Induced Neutropenia (2026)" was officially released.

From April 17 to 22, local time, the 2026 American Association for Cancer Research (AACR) Annual Meeting was held in San Diego. As one of the most influential academic events in the global oncology research field, LaNova Medicines, a wholly-owned subsidiary of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), disclosed for the first time key preclinical research data for two globally competitive next-generation antibody-drug conjugates (ADCs) - LM-364TME and LM-338.

From April 17 to 22, local time, the 2026 American Association for Cancer Research (AACR) Annual Meeting was held in San Diego, USA. LaNova Medicines, a wholly-owned subsidiary of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), announced for the first time preliminary clinical data for its independently developed innovative drug MK-2010/LM-299 (a PD-1/VEGF bispecific antibody).

On April 17, the official website of the National Medical Products Administration (NMPA) showed that the 4th indication for the Class 1 new drug "Defu Combination" from CTTQ, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK)—Benmelstobart combined with Anlotinib capsules—has been approved for marketing for the treatment of advanced or unresectable alveolar soft tissue sarcoma (ASPS).